Literature DB >> 16650144

Differential actions of NPY on seizure modulation via Y1 and Y2 receptors: evidence from receptor knockout mice.

En-Ju Deborah Lin1, Deborah Young, Kristin Baer, Herbert Herzog, Matthew J During.   

Abstract

PURPOSE: Neuropeptide Y (NPY) has been shown to modulate seizure activities. To provide further understanding of the involvement of two of the most abundantly expressed NPY receptors, Y1 and Y2, we assessed the effect of Y1 and Y2 gene deletion on systemic kainic acid-induced seizures. We also examined the effect of rAAV-mediated hippocampal NPY overexpression on seizure susceptibility in these receptor knockout mice.
METHODS: Recombinant adeno-associated viral vector overexpressing NPY (rAAV-NPY) or an empty vector control (rAAV-Empty) was injected into the hippocampus of adult C57BL/6-129/SvJ wild-type male mice and mice deficient of Y1 or Y2 receptors on the same background. Four weeks after vector injection, mice were subjected to systemic kainic acid-induced seizures, and the seizure behaviors were scored.
RESULTS: The rAAV-mediated hippocampal overexpression of NPY led to a twofold reduction in seizures induced by systemic kainic acid in wild-type mice and Y1 receptor knockout mice but not in mice deficient of Y2 receptors. A differential action by the receptors was observed in the seizure-induced mortality rate, with increased fatality in Y2-/- mice. In addition, although NPY overexpression did not significantly affect the mortality rate in Y2-/- and wild-type mice, it abolished KA-induced mortality in Y1-/-mice.
CONCLUSIONS: This study shows for the first time an altered susceptibility to chemically induced seizures in Y1 and Y2 knockout mice and demonstrates a differential seizure modulation mediated by these receptors via a genetic approach.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16650144     DOI: 10.1111/j.1528-1167.2006.00500.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  19 in total

Review 1.  Current prospects and challenges for epilepsy gene therapy.

Authors:  Marc S Weinberg; Thomas J McCown
Journal:  Exp Neurol       Date:  2011-10-08       Impact factor: 5.330

2.  Cell and gene therapies for refractory epilepsy.

Authors:  Detlev Boison
Journal:  Curr Neuropharmacol       Date:  2007       Impact factor: 7.363

3.  Molecular alterations in areas generating fast ripples in an animal model of temporal lobe epilepsy.

Authors:  Kellen D Winden; Anatol Bragin; Jerome Engel; Dan H Geschwind
Journal:  Neurobiol Dis       Date:  2015-03-25       Impact factor: 5.996

4.  Neuropeptide Y has a protective role during murine retrovirus-induced neurological disease.

Authors:  Min Du; Niranjan B Butchi; Tyson Woods; Timothy W Morgan; Karin E Peterson
Journal:  J Virol       Date:  2010-08-11       Impact factor: 5.103

5.  Aging and excitotoxic stress exacerbate neural circuit reorganization in amyloid precursor protein intracellular domain transgenic mice.

Authors:  Kaushik Ghosal; Sanjay W Pimplikar
Journal:  Neurobiol Aging       Date:  2010-05-20       Impact factor: 4.673

6.  Adeno-associated virus-mediated expression and constitutive secretion of NPY or NPY13-36 suppresses seizure activity in vivo.

Authors:  S Foti; R P Haberman; R J Samulski; T J McCown
Journal:  Gene Ther       Date:  2007-08-23       Impact factor: 5.250

7.  NPY Y1 receptors differentially modulate GABAA and NMDA receptors via divergent signal-transduction pathways to reduce excitability of amygdala neurons.

Authors:  Andrei I Molosh; Tammy J Sajdyk; William A Truitt; Weiguo Zhu; Gerry S Oxford; Anantha Shekhar
Journal:  Neuropsychopharmacology       Date:  2013-01-28       Impact factor: 7.853

Review 8.  How do seizures stop?

Authors:  Fred A Lado; Solomon L Moshé
Journal:  Epilepsia       Date:  2008-05-21       Impact factor: 5.864

9.  Hippocampal NPY gene transfer attenuates seizures without affecting epilepsy-induced impairment of LTP.

Authors:  Andreas T Sørensen; Litsa Nikitidou; Marco Ledri; En-Ju D Lin; Matthew J During; Irene Kanter-Schlifke; Merab Kokaia
Journal:  Exp Neurol       Date:  2008-11-10       Impact factor: 5.330

Review 10.  Gene therapy in epilepsy.

Authors:  Véronique Riban; Helen L Fitzsimons; Matthew J During
Journal:  Epilepsia       Date:  2008-08-19       Impact factor: 5.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.